|
1
|
Kim SY, Hur MS, Choi BG, Kim MJ, Lee YW,
Choe YB and Ahn KJ: A preliminary study of new single polymorphisms
in the T helper type 17 pathway for psoriasis in the Korean
population. Clin Exp Immunol. 187:251–258. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Batani A, Brănișteanu DE, Ilie MA, Boda D,
Ianosi S, Ianosi G and Caruntu C: Assessment of dermal papillary
and microvascular parameters in psoriasis vulgaris using in vivo
reflectance confocal microscopy. Exp Ther Med. 15:1241–1246.
2018.PubMed/NCBI
|
|
3
|
Boda D, Negrei C, Nicolescu F and Balalau
C: Assessment of some oxidative stress parameters in methotrexate
treated psoriasis patients. Farmacia. 62:704–710. 2014.
|
|
4
|
Batalla A, Coto E, González-Lara L,
González-Fernández D, Gómez J, Aranguren TF, Queiro R,
Santos-Juanes J, López-Larrea C and Coto-Segura P: Association
between single nucleotide polymorphisms IL17RA rs4819554 and IL17E
rs79877597 and psoriasis in a Spanish cohort. J Dermatol Sci.
80:111–115. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Căruntu C: Boda D, Căruntu A, Rotaru M,
Baderca F and Zurac S: In vivo imaging techniques for psoriatic
lesions. Rom J Morphol Embryol. 55 (Suppl 3):1191–1196.
2014.PubMed/NCBI
|
|
6
|
Bilal J, Berlinberg A, Bhattacharjee S,
Trost J, Riaz IB and Kurtzman DJB: A systematic review and
meta-analysis of the efficacy and safety of the interleukin
(IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab,
ixekizumab, brodalumab, guselkumab and tildrakizumab for the
treatment of moderate to severe plaque psoriasis. J Dermatolog
Treat. 29:569–578. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Coto E, Santos-Juanes J, Coto-Segura P and
Alvarez V: New psoriasis susceptibility genes: Momentum for
skin-barrier disruption. J Invest Dermatol. 131:1003–1005. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tsoi LC, Spain SL, Knight J, Ellinghaus E,
Stuart PE, Capon F, Ding J, Li Y, Tejasvi T, Gudjonsson JE, et al
Collaborative Association Study of Psoriasis (CASP); Genetic
Analysis of Psoriasis Consortium; Psoriasis Association Genetics
Extension; Wellcome Trust Case Control Consortium 2, :
Identification of 15 new psoriasis susceptibility loci highlights
the role of innate immunity. Nat Genet. 44:1341–1348. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yin X, Low HQ, Wang L, Li Y, Ellinghaus E,
Han J, Estivill X, Sun L, Zuo X, Shen C, et al: Genome-wide
meta-analysis identifies multiple novel associations and ethnic
heterogeneity of psoriasis susceptibility. Nat Commun. 6:69162015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Harden JL, Krueger JG and Bowcock AM: The
immunogenetics of psoriasis: A comprehensive review. J Autoimmun.
64:66–73. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Strange A, Capon F, Spencer CC, Knight J,
Weale ME, Allen MH, Barton A, Band G, Bellenguez C, Bergboer JG, et
al Genetic Analysis of Psoriasis Consortium and the Wellcome Trust
Case Control Consortium 2, : A genome-wide association study
identifies new psoriasis susceptibility loci and an interaction
between HLA-C and ERAP1. Nat Genet. 42:985–990. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Anbunathan H and Bowcock AM: The molecular
revolution in cutaneous biology: The era of genome-wide association
studies and statistical, big data, and computational topics. J
Invest Dermatol. 137:e113–e118. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lønnberg AS, Zachariae C and Skov L:
Targeting of interleukin-17 in the treatment of psoriasis. Clin
Cosmet Investig Dermatol. 7:251–259. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Malakouti M, Brown GE, Wang E, Koo J and
Levin EC: The role of IL-17 in psoriasis. J Dermatolog Treat.
26:41–44. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nestle FO, Kaplan DH and Barker J:
Psoriasis. N Engl J Med. 361:496–509. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shibata S, Saeki H, Tsunemi Y, Kato T,
Nakamura K, Kakinuma T, Kagami S, Fujita H, Tada Y, Sugaya M, et
al: IL-17F single nucleotide polymorphism is not associated with
psoriasis vulgaris or atopic dermatitis in the Japanese population.
J Dermatol Sci. 53:163–165. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Girolomoni G, Mrowietz U and Paul C:
Psoriasis: Rationale for targeting interleukin-17. Br J Dermatol.
167:717–724. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang L, Anderson DE, Baecher-Allan C,
Hastings WD, Bettelli E, Oukka M, Kuchroo VK and Hafler DA: IL-21
and TGF-beta are required for differentiation of human T(H)17
cells. Nature. 454:350–352. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gaffen SL, Kramer JM, Yu JJ and Shen F:
The IL-17 cytokine family. Vitam Horm. 74:255–282. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Miossec P and Kolls JK: Targeting IL-17
and TH17 cells in chronic inflammation. Nat Rev Drug Discov.
11:763–776. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tesmer LA, Lundy SK, Sarkar S and Fox DA:
Th17 cells in human disease. Immunol Rev. 223:87–113. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Patel DD, Lee DM, Kolbinger F and Antoni
C: Effect of IL-17A blockade with secukinumab in autoimmune
diseases. Ann Rheum Dis. 72 (Suppl 2):ii116–ii123. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Leipe J, Grunke M, Dechant C, Reindl C,
Kerzendorf U, Schulze-Koops H and Skapenko A: Role of Th17 cells in
human autoimmune arthritis. Arthritis Rheum. 62:2876–2885. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Miossec P, Korn T and Kuchroo VK:
Interleukin-17 and type 17 helper T cells. N Engl J Med.
361:888–898. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gaffen SL: Recent advances in the IL-17
cytokine family. Curr Opin Immunol. 23:613–619. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gaffen SL: Structure and signalling in the
IL-17 receptor family. Nat Rev Immunol. 9:556–567. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wright JF, Bennett F, Li B, Brooks J,
Luxenberg DP, Whitters MJ, Tomkinson KN, Fitz LJ, Wolfman NM,
Collins M, et al: The human IL-17F/IL-17A heterodimeric cytokine
signals through the IL-17RA/IL-17RC receptor complex. J Immunol.
181:2799–2805. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chiricozzi A: Pathogenic role of IL-17 in
psoriasis and psoriatic arthritis. Actas Dermosifiliogr. 105 (Suppl
1):9–20. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Starnes T, Robertson MJ, Sledge G, Kelich
S, Nakshatri H, Broxmeyer HE and Hromas R: Cutting edge: IL-17F, a
novel cytokine selectively expressed in activated T cells and
monocytes, regulates angiogenesis and endothelial cell cytokine
production. J Immunol. 167:4137–4140. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Arisawa T, Tahara T, Shibata T, Nagasaka
M, Nakamura M, Kamiya Y, Fujita H, Nakamura M, Yoshioka D, Arima Y,
et al: The influence of polymorphisms of interleukin-17A and
interleukin-17F genes on the susceptibility to ulcerative colitis.
J Clin Immunol. 28:44–49. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kawaguchi M, Adachi M, Oda N, Kokubu F and
Huang SK: IL-17 cytokine family. J Allergy Clin Immunol.
114:1265–1274. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Prieto-Pérez R, Solano-López G, Cabaleiro
T, Román M, Ochoa D, Talegón M, Baniandrés O, López Estebaranz JL,
de la Cueva P, Daudén E, et al: The polymorphism rs763780 in the
IL-17F gene is associated with response to biological drugs in
patients with psoriasis. Pharmacogenomics. 16:1723–1731. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chiricozzi A, Guttman-Yassky E,
Suárez-Fariñas M, Nograles KE, Tian S, Cardinale I, Chimenti S and
Krueger JG: Integrative responses to IL-17 and TNF-α in human
keratinocytes account for key inflammatory pathogenic circuits in
psoriasis. J Invest Dermatol. 131:677–687. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Batalla A, Coto E, Gómez J, Eirís N,
González-Fernández D, Gómez-De Castro C, Daudén E, Llamas-Velasco
M, Prieto-Perez R, Abad-Santos F, et al: IL17RA gene variants and
anti-TNF response among psoriasis patients. Pharmacogenomics J.
18:76–80. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Martin DA, Towne JE, Kricorian G, Klekotka
P, Gudjonsson JE, Krueger JG and Russell CB: The emerging role of
IL-17 in the pathogenesis of psoriasis: Preclinical and clinical
findings. J Invest Dermatol. 133:17–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Harper EG, Guo C, Rizzo H, Lillis JV,
Kurtz SE, Skorcheva I, Purdy D, Fitch E, Iordanov M and Blauvelt A:
Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro
and in vivo: Implications for psoriasis pathogenesis. J Invest
Dermatol. 129:2175–2183. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Roostaeyan O, Kivelevitch D and Menter A:
A review article on brodalumab in the treatment of
moderate-to-severe plaque psoriasis. Immunotherapy. 9:963–978.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Korn T, Bettelli E, Oukka M and Kuchroo
VK: IL-17 and Th17 Cells. Annu Rev Immunol. 27:485–517. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pukelsheim K, Stoeger T, Kutschke D,
Ganguly K and Wjst M: Cytokine profiles in asthma families depend
on age and phenotype. PLoS One. 5:e142992010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ramirez-Carrozzi V, Sambandam A, Luis E,
Lin Z, Jeet S, Lesch J, Hackney J, Kim J, Zhou M, Lai J, et al:
IL-17C regulates the innate immune function of epithelial cells in
an autocrine manner. Nat Immunol. 12:1159–1166. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fujishima S, Watanabe H, Kawaguchi M,
Suzuki T, Matsukura S, Homma T, Howell BG, Hizawa N, Mitsuya T,
Huang SK, et al: Involvement of IL-17F via the induction of IL-6 in
psoriasis. Arch Dermatol Res. 302:499–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wilson NJ, Boniface K, Chan JR, McKenzie
BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel
F, et al: Development, cytokine profile and function of human
interleukin 17-producing helper T cells. Nat Immunol. 8:950–957.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chan JR, Blumenschein W, Murphy E, Diveu
C, Wiekowski M, Abbondanzo S, Lucian L, Geissler R, Brodie S,
Kimball AB, et al: IL-23 stimulates epidermal hyperplasia via TNF
and IL-20R2-dependent mechanisms with implications for psoriasis
pathogenesis. J Exp Med. 203:2577–2587. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Prieto-Pérez R, Cabaleiro T, Daudén E,
Ochoa D, Roman M and Abad-Santos F: Genetics of psoriasis and
pharmacogenetics of biological drugs. Autoimmune Dis.
2013:6130862013.PubMed/NCBI
|
|
45
|
Asarch A, Barak O, Loo DS and Gottlieb AB:
Th17 cells: A new therapeutic target in inflammatory dermatoses. J
Dermatolog Treat. 19:318–326. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kagami S, Rizzo HL, Lee JJ, Koguchi Y and
Blauvelt A: Circulating Th17, Th22, and Th1 cells are increased in
psoriasis. J Invest Dermatol. 130:1373–1383. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Johansen C, Usher PA, Kjellerup RB,
Lundsgaard D, Iversen L and Kragballe K: Characterization of the
interleukin-17 isoforms and receptors in lesional psoriatic skin.
Br J Dermatol. 160:319–324. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Białecka M, Ostasz R, Kurzawski M,
Klimowicz A, Fabiańczyk H, Bojko P, Dziedziejko V, Safranow K,
Machoy-Mokrzyńska A and Droździk M: IL17A and IL17F gene
polymorphism association with psoriasis risk and response to
treatment in a Polish population. Dermatology. 232:592–596. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Raţiu MP, Purcărea I, Popa F, Purcărea VL,
Purcărea TV, Lupuleasa D and Boda D: Escaping the economic turn
down through performing employees, creative leaders and growth
driver capabilities in the Romanian pharmaceutical industry.
Farmacia. 59:119–130. 2011.
|
|
50
|
Caruntu C, Boda D, Dumitrascu G,
Constantin C and Neagu M: Proteomics focusing on immune markers in
psoriatic arthritis. Biomarkers Med. 9:513–528. 2015. View Article : Google Scholar
|
|
51
|
Negrei C, Caruntu C, Ginghina O,
Dragomiroiu GTAB, Toderescu CD and Boda D: Qualitative and
quantitative determination of methotrexate polyglutamates in
erythrocytes by high performance liquid chromatography. Rev Chim.
66:607–610. 2015.
|
|
52
|
Negrei C, Ginghină O, Căruntu C, Burcea
Dragomiroiu GTA, Jinescu G and Boda D: Investigation relevance of
methotrexate polyglutamates in biological systems by high
performance liquid chromatography. Rev Chim. 66:766–768. 2015.
|
|
53
|
Negrei C, Arsene AL, Toderescu CD, Boda B
and Ilie M: Acitretin treatment in psoriazis may influence the cell
membrane fluidity. Farmacia. 60:767–771. 2012.
|
|
54
|
Thomas LW, Lee EB and Wu JJ: Systematic
review of anti-drug antibodies of IL-17 inhibitors for psoriasis. J
Dermatolog Treat. 18:1–7. 2018.
|
|
55
|
Liu L, Lu J, Allan BW, Tang Y, Tetreault
J, Chow CK, Barmettler B, Nelson J, Bina H, Huang L, et al:
Generation and characterization of ixekizumab, a humanized
monoclonal antibody that neutralizes interleukin-17A. J Inflamm
Res. 9:39–50. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kemény L, Berggren L, Dossenbach M,
Dutronc Y and Paul C: Efficacy and safety of ixekizumab in patients
with plaque psoriasis across different degrees of disease severity:
Results from UNCOVER-2 and UNCOVER-3. J Dermatolog Treat. 4:1–8.
2018.
|
|
57
|
Gordon KB, Blauvelt A, Papp KA, Langley
RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, et al
UNCOVER-1 Study Group, : UNCOVER-2 Study Group; UNCOVER-3 Study
Group: Phase 3 trials of ixekizumab in moderate-to-severe plaque
psoriasis. N Engl J Med. 375:345–356. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Griffiths CE, Reich K, Lebwohl M, van de
Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L,
Secrest RJ, et al UNCOVER-2 and UNCOVER-3 investigators, :
Comparison of ixekizumab with etanercept or placebo in
moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results
from two phase 3 randomised trials. Lancet. 386:541–551. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Olteanu R, Zota A and Constantin M:
Biosimilars: An update on clinical trials (review of published and
ongoing studies). Acta Dermatovenerol Croat. 25:57–66.
2017.PubMed/NCBI
|
|
60
|
Nair RP, Stuart PE, Nistor I, Hiremagalore
R, Chia NVC, Jenisch S, Weichenthal M, Abecasis GR, Lim HW,
Christophers E, et al: Sequence and haplotype analysis supports
HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet.
78:827–851. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
61
|
Nishikawa R, Nagai H, Bito T, Ikeda T,
Horikawa T, Adachi A, Matsubara T and Nishigori C: Genetic
prediction of the effectiveness of biologics for psoriasis
treatment. J Dermatol. 43:1273–1277. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Park H, Li Z, Yang XO, Chang SH, Nurieva
R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, et al: A distinct
lineage of CD4 T cells regulates tissue inflammation by producing
interleukin 17. Nat Immunol. 6:1133–1141. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Olteanu R, Constantin MM, Zota A,
Dorobantu DM, Constantin T, Serban ED, Balanescu P, Mihele D and
Gheuca-Solovastru L: Original clinical experience and approach to
treatment study with interleukin 12/23 inhibitor in
moderate-to-severe psoriasis patients. Farmacia. 64:918–921.
2016.
|
|
64
|
Catanoso MG, Boiardi L, Macchioni P,
Garagnani P, Sazzini M, De Fanti S, Farnetti E, Casali B,
Chiarolanza I, Nicoli D, et al: IL-23A, IL-23R, IL-17A and IL-17R
polymorphisms in different psoriatic arthritis clinical
manifestations in the northern Italian population. Rheumatol Int.
33:1165–1176. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Căruntu C, Boda D, Musat S, Căruntu A and
Mandache E: Stress-induced mast cell activation in glabrous and
hairy skin. Mediators Inflamm. 2014:1–9. 2014. View Article : Google Scholar
|
